Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of everolimus and trastuzumab when
given together with letrozole in treating patients with hormone receptor-positive and human
epidermal growth factor (EGF) receptor 2 (HER2)-positive breast cancer or other solid tumors
that have spread to other places in the body. Everolimus may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of
breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the
use of estrogen by tumor cells. Immunotherapy with monoclonal antibodies, such as
trastuzumab, may induce changes in the body's immune system and may interfere with the
ability of tumor cells to grow and spread. Giving everolimus, letrozole, and trastuzumab
together may be a better treatment for breast cancer and other solid tumors than everolimus
alone.